Cancer vaccines hold great promise for improved cancer treatment. However, endosomal
trapping and low immunogenicity of tumour antigens usually limit the efficiency of …

The generation of tumour-specific T cells is critically important for cancer immunotherapy,. A
major challenge in achieving a robust T-cell response is the spatiotemporal orchestration of …

Nanovaccine‐based immunotherapy (NBI) has received greater attention recently for its
potential to prime tumor‐specific immunity and establish a long‐term immune memory that …

Cancer immunotherapy harnesses the immune system to attack tumors and has received
extensive attention in recent years. Cancer vaccines as an important branch of …

Vaccines hold tremendous potential for cancer immunotherapy by treating the immune
system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or …

Cancer immunotherapies including cancer vaccines, immune checkpoint blockade or
chimeric antigen receptor T cells have been exploited as the attractive treatment modalities …

To improve the response rate of immune checkpoint inhibitors such as anti-PD-L1 antibody
in immunosuppressive cancers like triple-negative breast cancer (TNBC), induction of …

Vaccines therapeutics manipulate host's immune system and have broad potential for
cancer prevention and treatment. However, due to poor immunogenicity and limited safety …

Neoantigen-based cancer vaccines are promising for boosting cytotoxic T lymphocyte (CTL)
responses. However, the therapeutic effect of cancer vaccines is severely blunted by …

Peptide-based neoantigen vaccines hold tremendous potential for personalized tumor
immunotherapy. However, effective delivery and controllable release of antigen peptides …